Meeting
2013 ASCO Annual Meeting
A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.
Authors
Brandon George Smaglo
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Brandon George Smaglo , Hongkun Wang , Kenneth Steadman , Joseph Murray , Michael Pishvaian , Aiwu Ruth He , Jimmy J. Hwang , Deepa Suresh Subramaniam , John F. Deeken , Louis M. Weiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS2624)
DOI
10.1200/jco.2013.31.15_suppl.tps2624
Abstract #
TPS2624
Poster Bd #
12D
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian
Poster
2015 Gastrointestinal Cancers Symposium
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
First Author: Enrique Sanz-Garcia
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska